322 related articles for article (PubMed ID: 24526271)
1. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders.
Zulauf CA; Sprich SE; Safren SA; Wilens TE
Curr Psychiatry Rep; 2014 Mar; 16(3):436. PubMed ID: 24526271
[TBL] [Abstract][Full Text] [Related]
2. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us?
Wilens TE; Monuteaux MC; Snyder LE; Moore H; Whitley J; Gignac M
J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):787-98. PubMed ID: 16262595
[TBL] [Abstract][Full Text] [Related]
3. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
[TBL] [Abstract][Full Text] [Related]
5. Everyday life consequences of substance use in adult patients with a substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD): a patient's perspective.
Kronenberg LM; Slager-Visscher K; Goossens PJ; van den Brink W; van Achterberg T
BMC Psychiatry; 2014 Sep; 14():264. PubMed ID: 25234344
[TBL] [Abstract][Full Text] [Related]
6. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
7. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues.
Wilens TE
Psychiatr Clin North Am; 2004 Jun; 27(2):283-301. PubMed ID: 15063998
[TBL] [Abstract][Full Text] [Related]
8. [ADHD in Adults and Comorbid Substance Use Disorder: Prevalence, Clinical Diagnostics and Integrated Therapy].
Dirks H; Scherbaum N; Kis B; Mette C
Fortschr Neurol Psychiatr; 2017 Jun; 85(6):336-344. PubMed ID: 28645126
[TBL] [Abstract][Full Text] [Related]
9. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
10. When ADHD and substance use disorders intersect: relationship and treatment implications.
Wilens TE; Fusillo S
Curr Psychiatry Rep; 2007 Oct; 9(5):408-14. PubMed ID: 17915081
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies for co-occurring ADHD and substance use disorders.
Mariani JJ; Levin FR
Am J Addict; 2007; 16 Suppl 1(Suppl 1):45-54; quiz 55-6. PubMed ID: 17453606
[TBL] [Abstract][Full Text] [Related]
12. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Klassen LJ; Bilkey TS; Katzman MA; Chokka P
Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
[TBL] [Abstract][Full Text] [Related]
13. Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.
Regnart J; Truter I; Meyer A
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):275-282. PubMed ID: 28686107
[TBL] [Abstract][Full Text] [Related]
14. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use.
Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():4-8. PubMed ID: 18307375
[TBL] [Abstract][Full Text] [Related]
15. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
16. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
17. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample.
Steinhausen HC; Bisgaard C
Eur Neuropsychopharmacol; 2014 Feb; 24(2):232-41. PubMed ID: 24314850
[TBL] [Abstract][Full Text] [Related]
18. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
19. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.
Crunelle CL; van den Brink W; Moggi F; Konstenius M; Franck J; Levin FR; van de Glind G; Demetrovics Z; Coetzee C; Luderer M; Schellekens A; ; Matthys F
Eur Addict Res; 2018; 24(1):43-51. PubMed ID: 29510390
[TBL] [Abstract][Full Text] [Related]
20. Genetic liability to ADHD and substance use disorders in individuals with ADHD.
Wimberley T; Agerbo E; Horsdal HT; Ottosen C; Brikell I; Als TD; Demontis D; Børglum AD; Nordentoft M; Mors O; Werge T; Hougaard D; Bybjerg-Grauholm J; Hansen MB; Mortensen PB; Thapar A; Riglin L; Langley K; Dalsgaard S
Addiction; 2020 Jul; 115(7):1368-1377. PubMed ID: 31803957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
